Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

Robert McWhirterMedicure IncMPH.VCOMMENTJan 06, 2017

$0.33 of earnings in 2016 is expected to more than double. Roughly a median estimate of $.82 against $10.45, about a 13X PE multiple. It has existing drugs with sales related to that.

$10.49

Stock price when the opinion was issued

$1.04

As of Jun 08, 2026. Market Open.

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

WEAK BUY
Just improved their cash position through a share sale. Have been approved in Canada to begin phase two trials for a hypertension product as well as being in phase two for their lead product. Well-positioned. Some technical concerns.
TRADE
Up 155% year-to-date and 12% on a 52-week basis. It's topping out now, finding a base. Having good support in the $1.50/1.60 range. Has about $10 million in cash, which is sufficient to get them through 2005. No revenue. Good partnerships.